Wall Street analysts forecast that Motif (NASDAQ:MTFB) will report earnings per share (EPS) of ($0.64) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have made estimates for Motif’s earnings, with the lowest EPS estimate coming in at ($0.82) and the highest estimate coming in at ($0.45). The firm is scheduled to report its next earnings results on Monday, January 1st.
According to Zacks, analysts expect that Motif will report full year earnings of ($2.46) per share for the current year, with EPS estimates ranging from ($3.02) to ($2.05). For the next fiscal year, analysts anticipate that the company will report earnings of ($2.20) per share, with EPS estimates ranging from ($3.00) to ($1.06). Zacks’ EPS averages are an average based on a survey of research analysts that follow Motif.
Several equities analysts have recently commented on MTFB shares. Northland Securities started coverage on Motif in a research report on Monday, April 16th. They issued an “outperform” rating on the stock. ValuEngine upgraded Motif from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. HC Wainwright restated a “buy” rating and issued a $32.00 price objective on shares of Motif in a research report on Thursday, April 19th. Finally, Gabelli reiterated a “hold” rating on shares of Motif in a research report on Thursday, March 29th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company. Motif has an average rating of “Hold” and a consensus target price of $19.50.
Shares of Motif stock traded up $9.75 during trading hours on Thursday, hitting $9.75. The company’s stock had a trading volume of 6,900 shares, compared to its average volume of 2,846. Motif has a 12-month low of $6.84 and a 12-month high of $13.75. The company has a market capitalization of $1.91 billion, a price-to-earnings ratio of -51.32 and a beta of 0.16. The company has a quick ratio of 0.96, a current ratio of 0.96 and a debt-to-equity ratio of -1.58.
Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is Iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus.
Get a free copy of the Zacks research report on Motif (MTFB)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Motif Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motif and related companies with MarketBeat.com's FREE daily email newsletter.